, Columnist
Beware Biogen’s Alzheimer’s Drug Resurrection
Reviving a failed treatment based on new data is a risky gambit, and approval is far from assured.
The biotech giant still faces an uphill battle.
Photographer: Scott Eisen/Bloomberg
This article is for subscribers only.
Just eight months after it announced the failure of its lead Alzheimer’s drug, aducanumab, Biogen Inc. is attempting to bring it back.
The biotech giant announced Tuesday that it plans to submit the drug for FDA approval based on “a new analysis of a larger dataset,” which showed that the drug was able to slow mental decline in some patients after all. It’s an astonishing turnaround that sent the stock surging some 40% in early trading.